Movement Disorder:生活方式,是否影响遗传性共济失调?

2022-01-16 Freeman MedSci原创

SCA3患者和对照组的生活方式因素的差异,以及生活方式因素与疾病严重程度的关联

脊髓小脑共济失调3型(SCA3)是最常见的显性遗传性共济失调,导致严重残疾和过早死亡。虽然目前还没有治愈性的治疗方法,但已经开发了几种减少突变蛋白的方法,试点试验似乎也指日可待。

尽管如此,对症治疗和病人咨询仍将是SCA3患者护理的基石。尽管在了解SCA3的自然史方面已经取得了重大进展,但观察到的疾病严重程度、进展和发病年龄的高变异性只能部分地用扩展等位基因的重复长度来解释。

这表明,其他遗传或环境因素,包括生活方式因素,可能有助于这种变异性。到目前为止,生活方式因素的作用仍不清楚,主要是由于缺乏对代表性队列的研究。除了了解SCA3的自然史外,该结果可能对即将进行的干预性试验和病人咨询的分层有影响。


藉此,图宾根大学的Holger Hengel等人,在这个多中心的前瞻性观察研究评估了243名SCA3患者的生活方式因素,包括饮酒、吸烟、体重指数(BMI)、身体活动和共济失调专用物理治疗,并探讨了与发病年龄、疾病严重程度和病情发展的可能关联。

藉此,图宾根大学的 Holger Hengel等人在这个前瞻性队列研究中,收集了243名SCA3患者和119名对照组的吸烟、饮酒、体育活动、物理治疗和体重指数(BMI)的数据,并测试了与发病年龄、疾病严重程度和病情发展的关系。

他们发现:与对照组相比,SCA3患者的活动量较少,饮酒量也较少。

较少的体力活动和戒酒与更严重的疾病有关,但与疾病进展率或发病年龄无关。吸烟、BMI或物理治疗与疾病参数没有关系。

该研究的重要意义在于发现了:SCA3患者和对照组的生活方式因素的差异,以及生活方式因素与疾病严重程度的关联,可能是由症状对行为的影响所驱动没有发现生活方式与疾病进展之间的关联。

 

原文出处:
Hengel H, Martus P, Faber J, et al. Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease Severity. Mov Disord. Published online October 29, 2021:mds.28844. doi:10.1002/mds.28844.

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2077674, encodeId=a6cd20e7674ed, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 16 06:33:52 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070046, encodeId=228320e0046dc, content=<a href='/topic/show?id=f44495115ca' target=_blank style='color:#2F92EE;'>#遗传性共济失调#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95115, encryptionId=f44495115ca, topicName=遗传性共济失调)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Jun 23 16:33:52 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013798, encodeId=b4512013e98d5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Mar 29 11:33:52 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784486, encodeId=d4351e844865d, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Sep 27 14:33:52 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860166, encodeId=d332186016629, content=<a href='/topic/show?id=cc73951054b' target=_blank style='color:#2F92EE;'>#遗传性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95105, encryptionId=cc73951054b, topicName=遗传性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 03 16:33:52 CST 2022, time=2022-06-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2077674, encodeId=a6cd20e7674ed, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 16 06:33:52 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070046, encodeId=228320e0046dc, content=<a href='/topic/show?id=f44495115ca' target=_blank style='color:#2F92EE;'>#遗传性共济失调#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95115, encryptionId=f44495115ca, topicName=遗传性共济失调)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Jun 23 16:33:52 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013798, encodeId=b4512013e98d5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Mar 29 11:33:52 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784486, encodeId=d4351e844865d, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Sep 27 14:33:52 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860166, encodeId=d332186016629, content=<a href='/topic/show?id=cc73951054b' target=_blank style='color:#2F92EE;'>#遗传性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95105, encryptionId=cc73951054b, topicName=遗传性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 03 16:33:52 CST 2022, time=2022-06-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2077674, encodeId=a6cd20e7674ed, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 16 06:33:52 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070046, encodeId=228320e0046dc, content=<a href='/topic/show?id=f44495115ca' target=_blank style='color:#2F92EE;'>#遗传性共济失调#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95115, encryptionId=f44495115ca, topicName=遗传性共济失调)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Jun 23 16:33:52 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013798, encodeId=b4512013e98d5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Mar 29 11:33:52 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784486, encodeId=d4351e844865d, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Sep 27 14:33:52 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860166, encodeId=d332186016629, content=<a href='/topic/show?id=cc73951054b' target=_blank style='color:#2F92EE;'>#遗传性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95105, encryptionId=cc73951054b, topicName=遗传性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 03 16:33:52 CST 2022, time=2022-06-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2077674, encodeId=a6cd20e7674ed, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 16 06:33:52 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070046, encodeId=228320e0046dc, content=<a href='/topic/show?id=f44495115ca' target=_blank style='color:#2F92EE;'>#遗传性共济失调#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95115, encryptionId=f44495115ca, topicName=遗传性共济失调)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Jun 23 16:33:52 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013798, encodeId=b4512013e98d5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Mar 29 11:33:52 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784486, encodeId=d4351e844865d, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Sep 27 14:33:52 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860166, encodeId=d332186016629, content=<a href='/topic/show?id=cc73951054b' target=_blank style='color:#2F92EE;'>#遗传性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95105, encryptionId=cc73951054b, topicName=遗传性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 03 16:33:52 CST 2022, time=2022-06-03, status=1, ipAttribution=)]
    2022-09-27 cmsvly
  5. [GetPortalCommentsPageByObjectIdResponse(id=2077674, encodeId=a6cd20e7674ed, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Wed Nov 16 06:33:52 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2070046, encodeId=228320e0046dc, content=<a href='/topic/show?id=f44495115ca' target=_blank style='color:#2F92EE;'>#遗传性共济失调#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95115, encryptionId=f44495115ca, topicName=遗传性共济失调)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Thu Jun 23 16:33:52 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013798, encodeId=b4512013e98d5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue Mar 29 11:33:52 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784486, encodeId=d4351e844865d, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Sep 27 14:33:52 CST 2022, time=2022-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860166, encodeId=d332186016629, content=<a href='/topic/show?id=cc73951054b' target=_blank style='color:#2F92EE;'>#遗传性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95105, encryptionId=cc73951054b, topicName=遗传性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Jun 03 16:33:52 CST 2022, time=2022-06-03, status=1, ipAttribution=)]

相关资讯

JNNP:RCF1相关共济失调是多系统萎缩的可能原因之一

多系统萎缩(MSA)是一种罕见的神经退行性疾病,结合不同的小脑损伤表现,帕金森病和自主神经功能障碍依赖于病理检查来确定诊断。一致诊断标准(SCDC)根据帕金森病(MSA-P)或小脑损伤(MSA-C)的

Mov Disord : 高科技穿戴设备,助力共济失调诊断

可穿戴式惯性传感器对明显的和前驱的SCA患者的过度步态变异性提供了敏感和特异的测量

Mov Disord : 湘雅医院:神经丝轻链蛋白,可有效预测共济失调

bNfL可作为一个潜在的生物标志物来预测遗传性共济失调的发病、严重程度和进展情况

Neurology:病例:MRI可为发作性共济失调的诊断线索

3岁女孩,表现为发作性共济失调1月。发热后可持续1-2天。MRI提示神经代谢性疾病(图A–L)。

JNNP:RNF170的突变导致前庭反射障碍的感觉性共济失调神经病变

感觉神经病或神经节病是一种周围神经病。背根神经节的原发性和选择性损伤导致了感觉神经元的神经突变性。感觉神经节病的鉴别诊断范围很窄,最近,双等位基因AAGGG在复制因子复合亚基1中的扩增已被确定为感觉性

AUTOPHAGY:自噬增强引发共济失调

共济失调是一种常染色体隐性疾病,其特点是共济失调,同时伴有小脑浦肯野细胞变性、免疫缺陷、易受X射线影响、易患癌症、不育和其他症状。它是由一个单一的基因--ATM(共济失调性端叶增生症突变)引起的。

拓展阅读

共济失调评估和评级量表(SARA)

共济失调评估和评级量表(SARA)

两种常见脑萎缩

脑组织体积缩小继发脑室和蛛网膜下隙扩大称为脑萎缩,脑灰质从20~50岁开始即可开始萎缩,大于65岁的老年人脑萎缩程度与痴呆并无线性相关关系。

Mov Disord : 高科技穿戴设备,助力共济失调诊断

可穿戴式惯性传感器对明显的和前驱的SCA患者的过度步态变异性提供了敏感和特异的测量

Mov Disord : 湘雅医院:神经丝轻链蛋白,可有效预测共济失调

bNfL可作为一个潜在的生物标志物来预测遗传性共济失调的发病、严重程度和进展情况

JNNP:RCF1相关共济失调是多系统萎缩的可能原因之一

多系统萎缩(MSA)是一种罕见的神经退行性疾病,结合不同的小脑损伤表现,帕金森病和自主神经功能障碍依赖于病理检查来确定诊断。一致诊断标准(SCDC)根据帕金森病(MSA-P)或小脑损伤(MSA-C)的

JNNP:RNF170的突变导致前庭反射障碍的感觉性共济失调神经病变

感觉神经病或神经节病是一种周围神经病。背根神经节的原发性和选择性损伤导致了感觉神经元的神经突变性。感觉神经节病的鉴别诊断范围很窄,最近,双等位基因AAGGG在复制因子复合亚基1中的扩增已被确定为感觉性

2023 AGI共识建议:共济失调的MR成像

共济失调全球倡议(AGI,Ataxia Global Initiative) · 2023-06-06

ACR适宜性标准:儿童共济失调

Expert Panel on Pediatric Imaging · 2022-11-01

2019 ACR适宜性标准:共济失调

美国放射治疗及肿瘤学会(ASTRO,American Society for Therapeutic Radiology and Oncology) · 2019-05-15

2018 共识文章:共济失调神经电生理评估日常实践

国外神经内科相关专家小组(统称) · 2018-04-14